SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 52 filers reported holding SAGE THERAPEUTICS INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $663,546 | -42.0% | 61,100 | 0.0% | 0.00% | – |
Q1 2024 | $1,145,014 | -13.5% | 61,100 | 0.0% | 0.00% | -100.0% |
Q4 2023 | $1,324,037 | +5.3% | 61,100 | 0.0% | 0.00% | 0.0% |
Q3 2023 | $1,257,438 | -56.2% | 61,100 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $2,872,922 | +13.2% | 61,100 | +1.0% | 0.00% | 0.0% |
Q1 2023 | $2,538,580 | +10.0% | 60,500 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $2,307,470 | -2.6% | 60,500 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $2,369,000 | -46.5% | 60,500 | -55.9% | 0.00% | -50.0% |
Q2 2022 | $4,430,000 | -29.3% | 137,162 | -27.5% | 0.00% | 0.0% |
Q1 2022 | $6,265,000 | +15.0% | 189,290 | +47.8% | 0.00% | 0.0% |
Q4 2021 | $5,447,000 | +35.9% | 128,055 | +41.6% | 0.00% | 0.0% |
Q3 2021 | $4,008,000 | +211.9% | 90,446 | +300.0% | 0.00% | +100.0% |
Q2 2021 | $1,285,000 | -98.1% | 22,614 | -97.4% | 0.00% | -96.6% |
Q1 2021 | $66,311,000 | +931.4% | 885,916 | +1092.1% | 0.03% | +866.7% |
Q4 2020 | $6,429,000 | +310.3% | 74,316 | +189.9% | 0.00% | +200.0% |
Q3 2020 | $1,567,000 | +46.4% | 25,631 | -0.4% | 0.00% | 0.0% |
Q2 2020 | $1,070,000 | -33.4% | 25,731 | -54.0% | 0.00% | 0.0% |
Q1 2020 | $1,607,000 | -28.1% | 55,941 | +80.7% | 0.00% | 0.0% |
Q4 2019 | $2,235,000 | -96.2% | 30,961 | -92.5% | 0.00% | -97.2% |
Q3 2019 | $58,167,000 | -25.9% | 414,618 | -3.3% | 0.04% | -26.5% |
Q2 2019 | $78,480,000 | +10.4% | 428,643 | -4.1% | 0.05% | +6.5% |
Q1 2019 | $71,107,000 | +57.4% | 447,072 | -5.2% | 0.05% | +35.3% |
Q4 2018 | $45,168,000 | -22.8% | 471,529 | +13.8% | 0.03% | -10.5% |
Q3 2018 | $58,519,000 | -18.5% | 414,296 | -9.7% | 0.04% | -24.0% |
Q2 2018 | $71,804,000 | -16.5% | 458,721 | -14.0% | 0.05% | -19.4% |
Q1 2018 | $85,954,000 | -10.2% | 533,642 | -8.1% | 0.06% | -8.8% |
Q4 2017 | $95,694,000 | +154.2% | 580,982 | -3.8% | 0.07% | +142.9% |
Q3 2017 | $37,643,000 | -31.1% | 604,219 | -11.9% | 0.03% | -33.3% |
Q2 2017 | $54,598,000 | +8.6% | 685,562 | -3.1% | 0.04% | +5.0% |
Q1 2017 | $50,285,000 | +3.8% | 707,537 | -25.5% | 0.04% | 0.0% |
Q4 2016 | $48,464,000 | +11.3% | 949,163 | +0.4% | 0.04% | +8.1% |
Q3 2016 | $43,544,000 | +37.1% | 945,582 | -10.3% | 0.04% | +37.0% |
Q2 2016 | $31,772,000 | +4.6% | 1,054,499 | +11.3% | 0.03% | +3.8% |
Q1 2016 | $30,379,000 | -43.2% | 947,562 | +3.2% | 0.03% | -43.5% |
Q4 2015 | $53,513,000 | +38.3% | 917,882 | +0.4% | 0.05% | +39.4% |
Q3 2015 | $38,693,000 | -22.6% | 914,285 | +33.5% | 0.03% | -19.5% |
Q2 2015 | $50,008,000 | +224.3% | 685,039 | +123.1% | 0.04% | +215.4% |
Q1 2015 | $15,420,000 | +68.7% | 306,997 | +23.0% | 0.01% | +62.5% |
Q4 2014 | $9,138,000 | +13.8% | 249,666 | -2.0% | 0.01% | +14.3% |
Q3 2014 | $8,028,000 | – | 254,852 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |